FDA Selects Agilent’s Dual-Mode Platform for MAQC Project
News Jan 13, 2006
The U.S. Food and Drug Administration has recently selected Agilent’s dual-mode platform as part of its Microarray Quality Control (MAQC) project, designed to provide quality control guidance to the microarray industry.
"Our vision is to be able to assess the proficiency of a laboratory in running good microarray experiments," said Dr. Leming Shi, computational chemist, National Center for Toxicological Research, FDA, and architect of the MAQC project.
"We’re glad to see Agilent in the project, and we see positive responses to the one-color data from Agilent. Experimental design is unified, compared with other platforms, so there’s a lot of value in having two sample mixtures to evaluate the platform."
"This is the first one-color data I’ve ever generated, and I’m excited about using it to make research decisions," said FDA scientist Tucker Patterson, Ph.D.
"The workflow is very similar to the two-color work we’ve been doing, so there’s been no disruption caused by the new platform."
3rd International Conference and Exhibition on Nanomedicine and Drug Delivery
Mar 13 - Mar 14, 2019
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019